Skip to main content

Senseonics Holdings, Inc.

For the period ended Dec 31, 2025. Filed Mar 2, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 2, 2026

SENS$9.80+14.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​​​
​SENSEONICS HOLDINGS, INC.
​By:/s/ Timothy T. Goodnow, Ph.D.
​​Timothy T. Goodnow, Ph.D.
​​President and Chief Executive Officer

Date: March 2, 2026

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Timothy T. Goodnow, Ph.D., and Rick Sullivan, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Senseonics Holdings, Inc., and any or all amendments (including post-effective amendments) thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​​​​​
Signature​ ​ ​Title​ ​ ​Date
​​​​​
/s/ Timothy T. Goodnow, Ph.D.​President, Chief Executive Officer and Director​March 2, 2026
Timothy T. Goodnow, Ph.D.​(Principal Executive Officer)​​
​​​​​
/s/ RICK SULLIVAN​Chief Financial Officer​March 2, 2026
Rick Sullivan​(Principal Financial Officer and Principal Accounting Officer)​​
​​​​​
/s/ Stephen P. DeFalco​Chairman of the Board of Directors​March 2, 2026
Stephen P. DeFalco​​​​
​​​​​
/s/ Steven Edelman, M.D.​Director​March 2, 2026
Steven Edelman, M.D.​​​​
​​​​​
/s/ Edward J. Fiorentino​Director​March 2, 2026
Edward J. Fiorentino​​​​
​​​​​
/s/ Douglas S. Prince​Director​March 2, 2026
Douglas S. Prince​​​​
​​​​​
/s/ Douglas A. roeder​Director​March 2, 2026
Douglas A. Roeder​​​​
​​​​​
/s/ FRANCINE KAUFMAN, M.D.​Director and Chief Medical Officer​March 2, 2026
Francine Kaufman, M.D.​​​​
​​​​​
/s/ SHARON D. LARKIN​Director​March 2, 2026
Sharon D. Larkin​​​​
​​​​​
/s/ BRIAN HANSEN​Director and Chief Commercial Officer​March 2, 2026
Brian Hansen​​​​
​​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.